Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early ...

Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...

Treatment with brensocatib 10 mg and 25 mg significantly reduced the annual rate of pulmonary exacerbations in patients with NCFB. The Food and Drug Administration (FDA) has approved Brinsupri ™ ...

Please provide your email address to receive an email when new articles are posted on . Diagnosis-related anxiety, depression or fear was reported by a larger proportion of women vs. men. After being ...

With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. The FDA has signed off on ...

Dr. Christopher J. Richards: A 47-year-old woman was evaluated at the outpatient pulmonary clinic of this hospital because of recurrent sinusitis with progressive cough and bronchiectasis. Since her ...

Credit: Insmed. Brensocatib is an oral, reversible inhibitor of dipeptidyl peptidase 1. Treatment with brensocatib 10mg and 25mg significantly reduced the annual rate of pulmonary exacerbations in ...